Related Experiment Video
Updated: Mar 21, 2026
Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
Published on: May 21, 2013
Critical Considerations for Mesenchymal Stem Cell-based Therapies in Osteoarthritis and Spinal Cord Injury: A
Shaolong Li1, Chenxi Zhao1, Wei Wang1
1Department of Orthopaedics, Qilu Hospital, Shandong University Centre for Orthopaedics, Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Shandong, China.
Abstract:
Mesenchymal stem cells (MSCs) have been proposed as treatments for degenerative diseases, but clinical outcomes have been inconsistent. Here, we reviewed the ClinicalTrials.gov database and identified ~1,600 trials associated with MSC-based therapies; osteoarthritis (OA) and spinal cord injury (SCI) were most frequently investigated, but the reporting of results was consistently low (<7%). We next searched the PubMed database and identified 26 OA and 16 SCI published trials, which included studies from one or both databases. Our analysis identified a common set of factors that influenced therapeutic efficacy in both diseases, including MSC source, donor type, dose/route & frequency of administration, and patient variation. Of these, three factors were significant for improving efficacy. MSC quality is affected by age of the donor, and this is especially important when treating older OA patients with autologous MSCs. Phase of the disease is important, and both OA and SCI may benefit from early treatment, since MSCs can ameliorate inflammation and initiate tissue repair. MSC source is critical as allogenic MSCs are no longer considered "immune privileged", and autologous cells can differentiate and repair damaged tissue without immune interference. The results of this narrative literature review suggest that establishing a personal autologous MSC bank may be an essential component for achieving success with MSC-based therapies, since MSCs from this repository could be deployed early, ameliorate inflammation, and initiate repair of damaged tissues.
Insights
Mesenchymal stem cell (MSC) therapies show inconsistent outcomes for degenerative diseases. Early treatment with autologous MSCs, considering donor age and disease phase, is key for improved therapeutic efficacy and tissue repair.
Area of Science:
- Regenerative Medicine
- Cell Therapy
- Biomedical Research
Background:
- Mesenchymal stem cells (MSCs) are investigated for degenerative diseases like osteoarthritis (OA) and spinal cord injury (SCI).
- Clinical outcomes for MSC-based therapies are inconsistent, with low reported results from trials.
- Over 1,600 trials involving MSCs were identified, with OA and SCI being the most common targets.
Purpose of the Study:
- To analyze factors influencing the efficacy of MSC-based therapies for degenerative diseases.
- To identify key parameters for improving therapeutic outcomes in OA and SCI.
- To review published literature and clinical trial data for insights into MSC therapy effectiveness.
Main Methods:
- Systematic review of ClinicalTrials.gov and PubMed databases.
- Identification and analysis of ~1,600 MSC-related trials.
- Literature search for 26 OA and 16 SCI published trials.
Main Results:
- Common factors influencing MSC efficacy include MSC source, donor type, dose/route/frequency, and patient variation.
- Three factors significantly improve therapeutic efficacy: donor age (especially for autologous MSCs in older OA patients), early disease phase for both OA and SCI, and MSC source (autologous preferred over allogeneic).
- Autologous MSCs can repair tissue without immune interference, unlike allogeneic MSCs.
Conclusions:
- Early intervention with autologous MSCs is crucial for maximizing therapeutic benefits in degenerative diseases.
- Establishing personal autologous MSC banks may enhance treatment success by providing readily available cells for early intervention.
- Optimizing MSC source, donor characteristics, and administration protocols is essential for consistent clinical outcomes.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:17Stem Cell Culture